Cumberland Pharmaceuticals Correlations
CPIX Stock | USD 4.47 0.03 0.67% |
The current 90-days correlation between Cumberland Pharmaceuticals and Prestige Brand Holdings is 0.26 (i.e., Modest diversification). The correlation of Cumberland Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Cumberland Pharmaceuticals Correlation With Market
Good diversification
The correlation between Cumberland Pharmaceuticals and DJI is -0.01 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Cumberland Pharmaceuticals and DJI in the same portfolio, assuming nothing else is changed.
Cumberland | Build AI portfolio with Cumberland Stock |
Moving together with Cumberland Stock
0.64 | PBH | Prestige Brand Holdings Earnings Call Tomorrow | PairCorr |
Moving against Cumberland Stock
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Cumberland Stock performing well and Cumberland Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cumberland Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
PBH | 1.46 | 0.18 | 0.14 | 0.16 | 1.47 | 2.38 | 17.76 | |||
EVO | 2.55 | 0.02 | 0.00 | (0.11) | 0.00 | 6.91 | 15.16 | |||
COLL | 1.75 | (0.16) | 0.00 | (0.37) | 0.00 | 3.47 | 11.87 | |||
ANIP | 1.78 | 0.39 | 0.20 | 0.41 | 1.93 | 4.40 | 19.27 | |||
PAHC | 2.74 | 0.01 | 0.00 | (0.12) | 0.00 | 6.60 | 18.36 | |||
PCRX | 2.27 | 0.13 | 0.05 | 0.02 | 2.57 | 4.41 | 22.99 | |||
RDY | 1.15 | 0.04 | 0.00 | (0.05) | 0.00 | 2.34 | 10.91 | |||
RGC | 19.58 | 8.92 | 0.84 | (4.11) | 8.23 | 62.58 | 265.55 |
Cumberland Pharmaceuticals Corporate Management
James Herman | Chief Compliance Officer and VP of National Accounts | Profile | |
John Hamm | Chief Officer | Profile | |
Christophe Bitterman | Vice Marketing | Profile | |
Todd Anthony | Vice Development | Profile | |
Adam Mostafa | Managing Relations | Profile | |
Erin Gull | Senior Associate | Profile |